Y-mAbs Therapeutics (YMAB) Tops Q1 EPS by 8c

Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q1 EPS of ($0.64), $0.08 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $10.5 million versus the consensus estimate of $10.9 million.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.

You May Also Be Interested In

• Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
• Bending Spoons S.p.A. (BSP) Tops Q2 EPS by 19c; offers guidance
• NextPlat Corp (NXPL) Reports Q2 Loss of $0.05